ZK 200775 hydrate

• 产品号: Z4777
• 分子式: C14H17F3N3O7P
• 分子量: 427.2696506
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: ZK 200775 hydrate
• IUPAC标准名: {[7-(morpholin-4-yl)-2,3-dioxo-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoxalin-1-yl]methyl}phosphonic acid hydrate
• IUPAC传统名: [7-(morpholin-4-yl)-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid hydrate
• 别名: MPQX; Fanapanel; [[3,4-Dihydro-7-(4-morpholinyl)-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-phosphonic acid hydrate

产品登记号

• MDL号: MFCD18452859

产品性质

• Empirical Formula (Hill Notation): C14H15F3N3O6P · xH2O
• 纯度: ≥98% (HPLC)
• 外观: off-white to light brown powder
• 溶解度: DMSO: ≥20 mg/mL
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

General description
ZK 200775 is a selective AMPA/kainite receptor antagonist with very low affinity for NMDA associated binding sites (Ki for CNQX binding site = 32 nM vs. 2.8 uM for DCKA binding site.) ZK 200775 displays superior PK and safety profiles in in vivo studies compared to quinoxalinedione antagonists such as NBQX, showing no effects on motor behavior or cardiac events at efficacious doses in rat. Additionally, unlike other quinoxalinediones, ZK 200775 is water soluble, making this a desirable tool compound for in vivo studies.

详细说明 (简体中文)

General description
ZK 200775 is a selective AMPA/kainite receptor antagonist with very low affinity for NMDA associated binding sites (Ki for CNQX binding site = 32 nM vs. 2.8 uM for DCKA binding site.) ZK 200775 displays superior PK and safety profiles in in vivo studies compared to quinoxalinedione antagonists such as NBQX, showing no effects on motor behavior or cardiac events at efficacious doses in rat. Additionally, unlike other quinoxalinediones, ZK 200775 is water soluble, making this a desirable tool compound for in vivo studies.